Corner Office Conversation With Umang Vohra, MD and Global CEO, Cipla
The life of Cipla, the Indian pharma giant, can broadly be divided into three parts: the first 8 decades of altruistic fervour; the second phase-a decade of sharper focus and soaring profits and the third upcoming phase of innovation, new frontiers and possible acquisitions. Steering the second two phases is the…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from The Morning Brief
See all episodes →
Similar episodes from other shows
More like The Morning Brief →
How can India’s pharma companies survive under Trump’s uncertainty?
Indian pharma: lofty aims in the midst of chaos
Why Tata 1mg thinks speed is the wrong bet in pharma
#470 AstraZeneca’s Vision for a Cancer-Free Future with Dr. Sanjeev Panchal
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.